PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor

NCT07442292 | Not Yet Recruiting DMC

• 1 other identifier: 2026KT10
• Study Type: observational
• Target: 40
• Locations: 0 countries
• Sites: N/A

Brief Summary

The objective of this study is to construct a noninvasive approach using radiolabbled peptide 68Ga-cPP-BCH PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.

Conditions

Melanoma Metastatic; PD-L1; PET / CT; Lung Cancer (NSCLC); Lung Cancer (SCLC); Melanoma (Skin Cancer)

Outcome Measures

Primary Outcomes (1)

• MPR

  major pathological response, in the surgical pathology after neo-adjuvant immunotherapy, the proportion of active tumors was less than 10%.

  3-6 months

Secondary Outcomes (1)

• ORR

  3-6 months

Study Arms (1)

Patients take 68Ga-cPP-BCH PET/CT before and after therapy

Patients take paired baseline 18F-FDG PET/CT and 68Ga-cPP-BCH PET/CT within 1 week; and take 68Ga-cPP-BCH PET/CT after therapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients with lung cancer, melanoma or other solid tumors scheduled for immunotherapy or combined immunotherapy; underwent PD-L1 IHC examination before therapy

You may qualify if:

• Aged 18-75, male and female, with ECOG score of 0 or 1;
• Subjects with lung cancer, melanoma, or other solid tumors scheduled for immunotherapy or combined immunotherapy;
• underwent PD-L1 IHC examination before therapy;
• The expected survival was more than 26 weeks;
• Blood routine test, liver and kidney function meet the following standards: blood routine: WBC \>= 4.0 x 10\^9/L or neutrophil \>= 1.5 x 10\^9/:, PLT \>= 100 x 10\^9 / L, Hb \>= 90g / L; Pt or APTT \<= 1.5 upper limit of normal value; liver and kidney function: total bilirubin \<= 1.5 x ULT (upper limit of normal value), ALT / AST \<= 2.5 upper limit of normal value or \<= 5 x ULT (subject with liver metastasis), ALP \<= 2.5 upper limit of normal value (if bone metastasis or liver metastasis exists, ALP \<= 4.5 upper limit of normal value); BUN \<= 1.5 x ULT, SCR \<= 1.5 x ULT;
• According to RECIST1.1, there was at least one measurable target lesion;
• Understand and sign informed consent voluntarily with good compliance.

You may not qualify if:

• The function of liver and kidney was seriously abnormal;
• Preparation for pregnant, pregnant and lactating women;
• Inability to lie flat for half an hour;
• Suffering from claustrophobia or other mental disorders;
• Other researchers considered it unsuitable to participate in the trial.

Sponsors & Collaborators

• Peking University Cancer Hospital & Institute: lead

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Hua Zhu, Professor

CONTACT

+86-010-88196495; zhuhuabch@pku.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: February 24, 2026
• First Posted: March 2, 2026
• Study Start: February 1, 2026
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): June 1, 2027
• Last Updated: March 5, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share